HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

F Vinas Selected Research

ErbB Receptors (EGF Receptor)

4/2016Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


F Vinas Research Topics

Disease

1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
04/2016
1Disease Progression
04/2016
1Neoplasms (Cancer)
04/2016
1Hypersensitivity (Allergy)
10/2010

Drug/Important Bio-Agent (IBA)

1Tyrosine Kinase InhibitorsIBA
04/2016
1ErbB Receptors (EGF Receptor)IBA
04/2016
1Proteins (Proteins, Gene)FDA Link
10/2010

Therapy/Procedure

1Therapeutics
04/2016